Key result
First-line therapy with combined epirubicin and vinorelbine for metastatic breast cancer yielded an objective response rate of 49.5% with manageable acute toxicity.
Why the study?
Does combined epirubicin and vinorelbine as first-line therapy improve objective response and have manageable tolerability in metastatic breast cancer?
Does combined epirubicin and vinorelbine as first-line therapy improve objective response and have manageable tolerability in metastatic breast cancer?
Combined epirubicin and vinorelbine shows a 49.5% objective response rate with manageable toxicity in metastatic breast cancer, though cardiotoxicity occurred in 15% of patients.
Answers are grounded in this paper and cite their sources.
May support further study in metastatic breast cancer; leaves open comparative efficacy versus standards in randomized trials.
This pilot study investigated the tolerability and efficacy of increasing doses of epirubicin and vinorelbine as first-line chemotherapy for metastatic breast cancer. Acute toxicity was manageable at all dose levels for combinations of epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8 repeated every 3 weeks. Myelotoxicity was the most frequent toxic event, with a significant increase in grade 4 leukopenia from 0% at dose level 1 (60+15 mg/m2) to 26% at dose level 6 (90+25 mg/m2). Signs of acute or chronic cardiotoxicity grades 2-4 were seen in 15% of the patients and included arrhythmia and decreased function. No significant association was established between dose and nonhematological toxicity. Objective responses were observed in 49 of the 99 evaluable patients (49.5%, 95% CI 39.9-59.2), 18 being complete and 31 partial responses. Responses were observed at all six dose levels. In conclusion, acute toxicity was manageable at all dose levels for combinations of epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8. In the treatment of advanced breast cancer, improvement of the antitumor efficacy by the addition of vinorelbine to epirubicin remains to be demonstrated in a randomized phase III trial.
No takes yet. Share an insight, caveat, or question.
Ejlertsen et al. (2003) studied metastatic breast cancer (n=99). epirubicin and vinorelbine was evaluated on Objective responses (95% CI 39.9-59.2). First-line therapy with combined epirubicin and vinorelbine for metastatic breast cancer yielded an objective response rate of 49.5% with manageable acute toxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: